Literature DB >> 11524397

Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators.

A L Chamis1, G E Peterson, C H Cabell, G R Corey, R A Sorrentino, R A Greenfield, T Ryan, L B Reller, V G Fowler.   

Abstract

BACKGROUND: Although cardiac device infections (CDIs) are a devastating complication of permanent pacemakers or implantable cardioverter-defibrillators, the incidence of CDI in patients with bacteremia is not well defined. The objective of this study was to determine the incidence of CDI among patients with permanent pacemakers or implantable cardioverter-defibrillators who develop Staphylococcus aureus bacteremia (SAB). METHODS AND
RESULTS: A cohort of all adult patients with SAB and permanent pacemakers or implantable cardioverter-defibrillators over a 6-year period was evaluated prospectively. The overall incidence of confirmed CDI was 15 of 33 (45.4%). Confirmed CDI occurred in 9 of the 12 patients (75%) with early SAB (<1 year after device placement). Fifteen of 21 patients (71.5%) with late SAB (>/=1 year after device placement) had either confirmed (6 of 21, 28.5%) or possible (9 of 21, 43%) CDI. In 60% of the patients (9 of 15) with confirmed CDI, no local signs or symptoms suggesting generator pocket infection were noted.
CONCLUSIONS: The incidence of CDI among patients with SAB and cardiac devices is high. Neither physical examination nor echocardiography can exclude the possibility of CDI. In patients with early SAB, the device is usually involved, and approximately 40% of these patients have obvious clinical signs of cardiac device involvement. Conversely, in patients with late SAB, the cardiac device is rarely the initial source of bacteremia, and there is a paucity of local signs of device involvement. The cardiac device is involved, however, in >/=28% of these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524397     DOI: 10.1161/hc3401.095097

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  35 in total

1.  Cardiac device-related endocarditis: Epidemiology, pathogenesis, diagnosis and treatment - a review.

Authors:  Shimon Edelstein; Malka Yahalom
Journal:  Int J Angiol       Date:  2009

2.  Septic shock induced from an implantable cardioverter-defibrillator lead-associated Candida albicans vegetation.

Authors:  Sandeep Hindupur; Anthony J Muslin
Journal:  J Interv Card Electrophysiol       Date:  2005-10       Impact factor: 1.900

3.  Detection of pacemaker and lead infection with FDG-PET.

Authors:  F J Vos; C P Bleeker-Rovers; A P J van Dijk; W J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-07       Impact factor: 9.236

4.  Management of infections involving implanted cardiac electrophysiologic devices.

Authors:  Frédéric L Paulin; Lorne J Gula; Raymond Yee; Allan C Skanes; George J Klein; Andrew D Krahn
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09

5.  Cardiovascular implantable device infections.

Authors:  George M Viola; Rabih O Darouiche
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

Review 6.  Transvenous Lead Extractions: Current Approaches and Future Trends.

Authors:  Adryan A Perez; Frank W Woo; Darren C Tsang; Roger G Carrillo
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-08

7.  The Diagnosis and Treatment of Pacemaker-Associated Infection.

Authors:  Michael Döring; Sergio Richter; Gerhard Hindricks
Journal:  Dtsch Arztebl Int       Date:  2018-06-29       Impact factor: 5.594

8.  The characteristics and outcome of infective endocarditis involving implantable cardiac devices.

Authors:  Eugene Athan
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

9.  New perspectives of infections in cardiovascular disease.

Authors:  Ignatius W Fong
Journal:  Curr Cardiol Rev       Date:  2009-05

10.  Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.

Authors:  Julie A Wu; Caroline Kusuma; James J Mond; John F Kokai-Kun
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.